Grant: $399,552 - National Institutes of Health - Sep. 11, 2009
0% voted satisfied - 100% voted not satisfied - 1 vote(s) cast
Award Description: Myeloproliferative disorders (MPDs) are a group of conditions characterized by chronic increases in some or all of the blood cells (platelets, white blood cells, and red blood cells). Recently, we and others have identified a mutation in the JAK2 tyrosine kinases in classic or Ph-negative MPDs including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The mutant enzyme designated JAK2V617F possesses deregulated and enhanced kinase activity and induces constitutive activation of downstream signaling events in transfected cells. We have now generated transgenic mice expressing the mutated enzyme in the hematopoietic system driven by a vav gene promoter. The transgenic mice displayed marked increases in blood counts and developed phenotypes that closely resembled human ET and PV in a transgene dose-dependent manner. The mice also developed PMF-like symptoms as they aged. Our data provides unequivocal evidence that JAK2V617F can cause MPDs and that the phenotypes are determined by the expression level of the mutant enzyme. Furthermore, by generating JAK2 transgenic mice and crossing them with JAK2V617F transgenic mice, we have found that over-expression of wild type JAK2 is not only non- pathogenic but also totally suppresses the pathogenic function of JAK2V617F, suggesting that wild type JAK2 antagonizes mutant JAK2V617F. These transgenic mouse models provide an invaluable tool to study MPDs and normal hematopoiesis. In this study, we will utilize these tools to reveal the pathological role of JAK2V617F, the molecular and cellular mechanism on which MPDs develop, and the interplay of mutant JAK2V617F with wild type JAK2. Specifically, we will fully characterize the phenotypes of JAK2V617F transgenic mice and reveal the dose-dependent nature of JAK2V617F-induced MPD phenotypes. We will thoroughly investigate the effects of JAK2V617F on the proliferation, differentiation, and survival of hematopoietic stem/progenitor cells by using various in vitro cell culture methods and in vivo stem cell transplant techniques and analyze the activation of various signaling pathways in these cells. We will study the antagonistic role of wild type JAK2 on the pathogenic function of JAK2V617F by characterizing the phenotypes of JAK2/JAK2V617F hybrid transgenic mice, investigating the interaction of JAK2 and JAK2V617F in vivo by using Mpl transgenic mice and in vitro by using cell-free systems and co-transfected cells. This study will provide novel insight into the mechanism by which abnormal hematopoiesis arises in MPD patients and normal hematopoiesis is regulated under healthy conditions. It addresses how HAK2V617F causes MPDs and answers the question why a single point mutation causes so many phenotypes. This study should have major implications in development of therapeutic drugs and procedures to treat MPDs in the future. We have generated novel and valuable tools and are in a unique position to finish such an important project. PUBLIC HEALTH RELEVANCE: This study concerns myeloproliferative disorders (MPDs) which represent a heterogeneous group of diseases characterized by increased proliferation of erythroid, megakaryocytic and/or myeloid lineages. We have identified an acquired mutation of tyrosine kinase JAK2 in these diseases and demonstrated the pathogenic role of the mutant enzyme by using transgenic mouse models. This study is intended to reveal how the mutant enzyme causes the disease. Understanding the pathogenic mechanism of the mutant enzyme will eventually allow us to develop therapeutic drugs and procedures to treat the diseases.
Project Description: As defined in the Award Description Field
Jobs Summary: No jobs created this quarter (Total jobs reported: 0)
Project Status: Not Started
This award's data was last updated on Sep. 11, 2009. Help expand these official descriptions using the wiki below.